Zai Lab Limited (ZLAB +1.1%) announces that it has received regulatory approval to commercialize Zejula (niraparib) in Macau for the treatment of adult patients with with platinum-sensitive relapsed high grade serous epithelial ovarian cancer who are in a complete or partial response to platinum-based chemotherapy.
The company in-licensed the PARP inhibitor from TESARO (GSK +0.9%) in September 2016 for the China market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.